NCT06437639View on ClinicalTrials.gov

MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)

PHASE4CompletedINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

November 29, 2023

Study Completion Date

February 2, 2024

Conditions

Primary Open-Angle Glaucoma (POAG)

Interventions

DRUG

Mexidol

Neurocytoprotector

Trial Locations (1)

625026

Tyumen Scientific Center of the Russian Academy of Sciences, Tyumen

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pharmasoft

INDUSTRY